Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Soticlestat (Primary) ; Soticlestat (Primary)
- Indications Dravet syndrome; Encephalitis; Lennox-Gastaut syndrome; Seizures
- Focus Therapeutic Use
- Acronyms ELEKTRA
- Sponsors Ovid Therapeutics; Takeda
- 05 May 2023 According to an Ovid Therapeutics media release post-hoc analysis data from this study were presented at the 2023 American Academy of Neurology meeting.
- 27 Apr 2023 Post hoc analysis results presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 16 Jul 2022 Results assessing efficacy and safety of soticlestat (TAK-935) as adjunctive therapy in children with syndrome or Lennox-Gastaut syndrome, published in the Epilepsia.